Want to see GB:GENI full AI Analyst Report?
GENI Stock Chart & Stats
0.80 p
0.03 p(3.13%)
At close: 4:00 PM EDT
0.80 p
0.03 p(3.13%)
Day’s Range― - ―
52-Week Range0.75 p - 5.50 p
Previous CloseN/A
Volume512.05K
Average Volume (3M)1.99M
Market Cap
£6.02M
Enterprise Value6.14 p
Total Cash (Recent Filing)£895.00K
Total Debt (Recent Filing)£146.00K
Price to Earnings (P/E)―
Beta-0.73
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume166,671
30 Day Avg. Volume1,986,185
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.70M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSustained revenue acceleration indicates growing clinical adoption and market traction for genomic tests. Over 2–6 months this trend supports operating leverage potential, enabling the company to spread fixed costs and improve unit economics as volumes rise if growth continues.
Improving Gross MarginA ~50% gross margin in diagnostics suggests a structurally profitable product mix once scale is reached. Higher gross margins provide durable cushion to invest in R&D and commercialization, and make future profitability more attainable as SG&A and R&D absorption improves.
Modest Absolute DebtLow absolute debt reduces near-term solvency pressure and interest expense burden, giving management flexibility to pursue non-dilutive funding or commercial initiatives. This structural debt position supports runway while revenue scales or during fundraising.
Bears Say
Large Net LossesDeep and persistent net losses materially undermine internal funding capacity and force recurring external financing. Over months this elevates dilution risk, constrains strategic investments, and increases execution risk if additional capital is delayed or costly.
Eroded Equity / Higher Leverage RatioA sharp equity decline tightens financial flexibility and raises creditor sensitivity; a higher debt-to-equity ratio limits borrowing capacity and can increase funding costs. Structurally, this makes future capital raises more dilutive or expensive, affecting long-term plans.
Persistent Negative Cash FlowChronic operating cash burn means the business is not self-sustaining and will rely on external financing. Over 2–6 months this pressure can force strategic trade-offs, defer product investments, and heighten execution risk if cash runway shortens or markets tighten.
GENinCode UK Ltd. News
GENI FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest share price was 0.75 p and its highest was 5.50 p in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is £6.02M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Sep 30, 2026 which is in 60 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Jun 08, 2026. The company reported -0.01 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -0.01 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in GB:GENI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.